These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9832347)
21. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Ulrich S; Neuhof S; Braun V; Meyer FP Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314 [TBL] [Abstract][Full Text] [Related]
22. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. Mann K; Bartels M; Gärtner HJ; Schied HW; Wagner W; Heimann H Pharmacopsychiatry; 1987 Jul; 20(4):155-9. PubMed ID: 2886997 [TBL] [Abstract][Full Text] [Related]
23. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Magliozzi JR; Hollister LE; Arnold KV; Earle GM Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835 [TBL] [Abstract][Full Text] [Related]
24. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695 [TBL] [Abstract][Full Text] [Related]
25. Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Kucharski LT; Alexander P; Tune L; Coyle J Psychopharmacology (Berl); 1984; 82(3):194-8. PubMed ID: 6144127 [TBL] [Abstract][Full Text] [Related]
26. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Volavka J; Cooper TB; Czobor P; Meisner M Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103 [TBL] [Abstract][Full Text] [Related]
27. Haloperidol plasma levels and dose optimization. Coryell W; Miller DD; Perry PJ Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338 [TBL] [Abstract][Full Text] [Related]
28. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment. Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460 [TBL] [Abstract][Full Text] [Related]
29. Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. de Oliveira IR; Dardennes RM; Amorim ES; Diquet B; de Sena EP; Moreira EC; de Castro-e-Silva EJ; Payan C; Fermanian J; Marcílio C Fundam Clin Pharmacol; 1995; 9(5):488-502. PubMed ID: 8617413 [TBL] [Abstract][Full Text] [Related]
30. Relations between psychotic symptoms and serum prolactin levels. Roncoroni D Pharmacopsychiatry; 1989 Mar; 22(2):71-5. PubMed ID: 2566181 [TBL] [Abstract][Full Text] [Related]
31. Haloperidol blood levels and clinical effects. Volavka J; Cooper T; Czobor P; Bitter I; Meisner M; Laska E; Gastanaga P; Krakowski M; Chou JC; Crowner M Arch Gen Psychiatry; 1992 May; 49(5):354-61. PubMed ID: 1586270 [TBL] [Abstract][Full Text] [Related]
32. Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients. Jain T; Bhandari A; Ram V; Sharma S; Parakh M; Parakh MC Clin Biochem; 2011 Jun; 44(8-9):675-80. PubMed ID: 21458435 [TBL] [Abstract][Full Text] [Related]
33. Haloperidol plasma concentrations in Taiwanese psychiatric patients. Lane HY; Lin HN; Hwu HG; Jann M; Hu WH; Chang WH J Formos Med Assoc; 1995 Nov; 94(11):671-8. PubMed ID: 8527974 [TBL] [Abstract][Full Text] [Related]
34. Haloperidol blood levels in acute mania with psychosis. Chou JC; Czobor P; Dacpano G; Richardson N; Tuma I; Trujillo M; Cooper TB; Volavka J J Clin Psychopharmacol; 2001 Aug; 21(4):445-7. PubMed ID: 11476130 [TBL] [Abstract][Full Text] [Related]
35. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Xiang YQ; Zhang ZJ; Weng YZ; Zhai YM; Li WB; Cai ZJ; Tan QR; Wang CY Schizophr Res; 2006 Apr; 83(2-3):201-10. PubMed ID: 16524698 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol. Pelton GH; Devanand DP; Bell K; Marder K; Marston K; Liu X; Cooper TB Am J Geriatr Psychiatry; 2003; 11(2):186-93. PubMed ID: 12611748 [TBL] [Abstract][Full Text] [Related]
37. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients. Rao ML; Brown WA Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222 [TBL] [Abstract][Full Text] [Related]
38. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524 [TBL] [Abstract][Full Text] [Related]
39. Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients. Aschauer HN; Schönbeck G; Langer G; Koinig G; Resch F; Hatzinger R; Chaudry HR; Sieghart W Pharmacopsychiatry; 1988 Sep; 21(5):246-51. PubMed ID: 3227055 [TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]